Eur Rev Med Pharmacol Sci 2018; 22 (19): 6545-6550
DOI: 10.26355/eurrev_201810_16070

Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate

M. Golino, F.R. Spera, L. Manfredonia, A. De Vita, A. Di Franco, P. Lamendola, A. Villano, V. Melita, E. Mencarelli, G.A. Lanza, F. Crea

Institute of Cardiology, Catholic University of the Sacred Heart, A. Gemelli Foundation, Rome, Italy. Gaetanoantonio.lanza@unicatt.it


OBJECTIVE: About one-third of patients undergoing percutaneous coronary interventions (PCIs) for flow-limiting coronary stenosis continue to develop signs of myocardial ischemia (MI) during exercise stress test [EST], despite successful coronary revascularization. Coronary microvascular dysfunction is a likely major cause of the persistence of EST-induced MI in these patients.

PATIENTS AND METHODS: We studied 15 patients (14 men, age 67±5 years) fulfilling the following strict inclusion criteria: (1) recent PCI (<6 months), with drug-eluting stent, of coronary artery stenoses for stable angina, with evidence of full success (no residual stenosis >20% in any vessel); (2) persistence of ST-segment depression induction during EST.

After a basal investigation, patients received either ranolazine (375 mg bid) or isosorbide-5-mononitrate (ISMN, 20 mg bid) for 3 weeks in a single-blind, randomized crossover study. Clinical assessment, symptom-limited EST, echocardiographic color-Doppler, with tissue-Doppler examination, and coronary microvascular dilator response to adenosine (CFR-ADO) and cold pressor test (CFR-CPT), assessed by transthoracic echo-Doppler, were obtained at baseline and the end of the 3-week therapy with each drug.

RESULTS: Compared to both baseline and ISMN, ranolazine showed a longer time to 1 mm ST-segment depression (404±116 s vs. 317±98 and 322±70 s, respectively; p<0.01). No differences were observed in coronary microvascular function and diastolic left ventricular function between the 2 drugs and compared to baseline.

CONCLUSIONS: Our data show that ranolazine, but not ISMN, improved time to ischemia during EST. This effect, however, was independent of any effects on coronary microvascular and diastolic function.

Free PDF Download

To cite this article

M. Golino, F.R. Spera, L. Manfredonia, A. De Vita, A. Di Franco, P. Lamendola, A. Villano, V. Melita, E. Mencarelli, G.A. Lanza, F. Crea
Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 19
Pages: 6545-6550
DOI: 10.26355/eurrev_201810_16070